DRG 287 Overview

DRG 287 covers inpatient admissions for circulatory system disorders excluding acute myocardial infarction that include a cardiac catheterization procedure and do not have a Major Complication or Comorbidity. This group captures a spectrum of diagnostic and interventional catheter-based evaluations for ischemic and nonischemic cardiac conditions. It is important for Medicare payment because the presence of cardiac catheterization raises resource use relative to noninvasive management, while the absence of a Major Complication or Comorbidity places cases in a mid-range reimbursement tier. Accurate coding of the catheterization and comorbid conditions directly affects grouping and payment under the Diagnosis-Related Group system.

Across commercial payers the observed rate range runs from about $11K to $24K across the middle quartiles, with payer maximums in the dataset up to $42K; the widest spread in observed payments appears between Anthem and BCBS in the full distribution. See the table and chart below for payer-level detail and percentile spreads. Note that payer names in the chart are shown as Aetna, Cigna, BCBS, and Anthem.

The CMS 2023 data represent national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($10.2k), average submitted covered charges ($61.0k), average Medicare payment ($7.5k), and total discharges (33.3k).

• Acute procedural optimization studies: randomized or prospective observational trials testing variations in cardiac catheterization technique, periprocedural antithrombotic strategies, vascular access management, or immediate adjunctive imaging in patients admitted with non–ST-elevation circulatory disorders (for example unstable angina, symptomatic ischemia but not AMI). These studies enroll inpatients undergoing diagnostic or therapeutic catheterization to evaluate short-term procedural outcomes (bleeding, contrast nephropathy, procedural success) and early resource utilization. Findings are directly relevant to clinicians and hospital payers because they can inform protocols that reduce complications, length of stay, and costly readmissions for this DRG cohort.
• Comparative effectiveness and care pathway trials: pragmatic trials or registry-linked comparative studies evaluating different inpatient management pathways (early catheterization versus delayed/conservative strategies, standardized chest pain observation protocols, or care bundles for patients with heart failure exacerbation who undergo cath). These studies target heterogeneous patients under DRG 287 who have circulatory disorders excluding AMI and seek to determine which pathways produce better in-hospital outcomes, lower complication rates, and more efficient use of catheterization resources. Results guide hospitals and payers in pathway selection and reimbursement planning by identifying approaches that maintain quality while reducing unnecessary testing, procedure utilization, and excess inpatient days.
• Post-discharge outcomes and transitional care research: cohort studies or randomized trials focused on discharge planning, medication reconciliation, cardiac rehabilitation enrollment, and outpatient follow-up timing for patients discharged after catheterization for non-AMI circulatory conditions. These studies assess medium- to long-term outcomes such as recurrent ischemic events, readmissions, adherence to secondary prevention, and cost-effectiveness of intensive transitional interventions. This area is crucial for payers and providers because improved post-discharge care can lower readmission rates and downstream costs for the DRG population while informing bundled payment and value-based reimbursement strategies.